Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy-Reference-Cited by-同舟云学术

Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy

Published:2024-08-27 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Muppidi Natasha,Adesoye Taiwo,Yi Min,Sun Susie X.,Chavez-MacGregor Mariana,Singh Puneet,Karuturi Meghan,Tamirisa Nina,Hunt Kelly K.,Teshome Mediget^ORCID

Funder

National Cancer Institute, National Institute of Health

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-16087-x.pdf

Reference16 articles.

1. Zeidman M, Schmidt H, Alberty-Oller JJ, et al. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB). Breast Cancer Res Treat. 2021. https://doi.org/10.1007/s10549-020-06041-2.

2. Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014. https://doi.org/10.1200/JCO.2013.53.1608.

3. Van Ramshorst M, der Heiden-van Van, der Loo M, Dackus GMHE, et al. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016. https://doi.org/10.1007/s10549-016-3878-9.

4. Templeton A, Ocaña A, Šeruga B, et al. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012. https://doi.org/10.1007/s10549-012-2236-9.

5. von Minckwitz G, Huang C, Mano M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1814017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ASO Author Reflections: Evolving Multidisciplinary Decision Making for Early-Stage, HER2-Positive Breast Cancer;Annals of Surgical Oncology;2024-09-09